Thursday, November 29, 2012

Regorafenib phase III results strongly support use in GIST

Regorafenib is effective for patients with gastrointestinal stromal tumors who have failed to respond to treatment with imatinib and sunitinib, trial results show.

via Med Wire News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)